Login to Your Account



Roche wins come-out roll with Eleven as other talks turn up cold table in IL-6

By Randy Osborne
Staff Writer

Wednesday, August 17, 2016

In January, after Eleven Biotherapeutics Inc. disclosed mixed phase III data in severe allergic conjunctivitis with the interleukin-1 signaling inhibitor EBI-005 – which also proved a dud in the late-stage experiment for dry eye disease in May 2015 – the stock took a 77 percent hit and Wall Street retreated.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription